ISB News

New Study on How Microbes Learn to Predict the Future

Adaptive Prediction of Yeast

July 28, 2017

In a study published in Genome Biology and Evolution, researchers at Institute for Systems Biology (ISB) designed an experiment to evolve novel adaptive prediction capability in yeast by repetitively exposing it to caffeine, followed by a toxin. Remarkably, the yeast cells learned the structure of this novel environmental pattern within as few as 50 generations to use caffeine as a cue for anticipating and mitigating lethal effects of the toxin.

3 Bullets:

  • Like plants and animals, even microbes can anticipate and prepare in advance for future changes in their environment
  • Similar to how Pavlov trained a dog to anticipate food when it heard a bell, ISB researchers trained yeast to anticipate a lethal toxin when it sensed caffeine
  • The study revealed how in a very short period of time yeast can evolve to ‘learn’ and ‘predict’ new patterns in their environment

Read More

Recent Articles

  • Dr. Sean Gibbons Promoted to Associate Professor

    Dr. Sean Gibbons – an expert in microbial ecology and evolution, computational systems biology, the human gut microbiome and its impacts on health, and head of ISB’s Gibbons Lab – has been promoted to Associate Professor. “Sean’s achievements since joining ISB in 2018 as a Washington Research Foundation Distinguished Investigator have been spectacular,” ISB President Dr. Jim Heath said. “With his focus on the microbiome, he brought a whole new…

  • AmeriCorps Member Sara Calder Joins ISB as Systems Health and STEM Coordinator

    Sara Calder recently joined ISB as Systems Health and STEM Coordinator, and is our second-ever AmeriCorps member. In this Q&A, Calder shares her education journey, her future plans, and much more.

  • In First-of-Its-Kind Trial, Scientists Use CRISPR to Treat Cancer

    Scientists for the first time have used CRISPR to substitute a gene to treat patients with cancer. The remarkable findings were published in the journal Nature and presented at the Society for Immunotherapy of Cancer (SITC) 2022.